BiotechTube
Leukos Biotech

Leukos Biotech

Barcelona, Spain· Est.
leukosbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Leukos Biotech is a private, preclinical-stage biotech company founded in 2016 and based in Barcelona, Spain. The company's core innovation is targeting the serotonin receptor 1B (HTR1B) on cancer stem cells and refractory cells, using a proprietary chemical space to develop novel therapeutics and companion diagnostics. Its lead asset, LB208, is being co-developed with AOP Health for indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and several solid tumors, with an IND expected in 2023. The company is backed by venture capital and non-profit foundation investors.

OncologyHematological MalignanciesSolid Tumors

Technology Platform

Proprietary drug discovery platform targeting the serotonin receptor 1B (HTR1B) on cancer stem cells and chemotherapy-resistant cells, with an associated companion diagnostic biomarker program.

Opportunities

LB208 targets cancer stem cells, addressing a root cause of relapse in cancers like AML and solid tumors with high unmet need.
The partnership with AOP Health provides development expertise and funding to advance the lead candidate into the clinic.
The companion diagnostic strategy enables a personalized medicine approach, potentially improving clinical trial success and commercial positioning.

Risk Factors

High scientific risk as HTR1B is a first-in-class target with unproven clinical efficacy and safety.
The company is heavily reliant on its single lead asset and the success of its partnership with AOP Health.
As a small, private company, it faces significant competition and capital constraints in the oncology field.

Competitive Landscape

Leukos competes in the crowded oncology space but differentiates by targeting HTR1B on cancer stem cells, a novel mechanism. It faces competition from other companies developing CSC-targeting therapies and broader AML/solid tumor treatments. Its partnership model and focus on a specific biological niche may help it navigate competition from larger biopharma players.

More companies in Oncology (General) →More companies in Spain →